FI89214B - Analysfoerfarande och diagnostiskt system foer ett markerande aemne foer abnorm lipidmetabolism - Google Patents
Analysfoerfarande och diagnostiskt system foer ett markerande aemne foer abnorm lipidmetabolism Download PDFInfo
- Publication number
- FI89214B FI89214B FI874253A FI874253A FI89214B FI 89214 B FI89214 B FI 89214B FI 874253 A FI874253 A FI 874253A FI 874253 A FI874253 A FI 874253A FI 89214 B FI89214 B FI 89214B
- Authority
- FI
- Finland
- Prior art keywords
- apolipoprotein
- solid
- apo
- molecules
- liquid
- Prior art date
Links
- 230000037356 lipid metabolism Effects 0.000 title claims description 23
- 238000004458 analytical method Methods 0.000 title description 3
- 102000005666 Apolipoprotein A-I Human genes 0.000 claims abstract description 162
- 108010059886 Apolipoprotein A-I Proteins 0.000 claims abstract description 162
- 108010008150 Apolipoprotein B-100 Proteins 0.000 claims abstract description 128
- 238000000034 method Methods 0.000 claims abstract description 66
- 210000004408 hybridoma Anatomy 0.000 claims abstract description 61
- 102000006991 Apolipoprotein B-100 Human genes 0.000 claims abstract 22
- 102100040202 Apolipoprotein B-100 Human genes 0.000 claims description 109
- 239000007790 solid phase Substances 0.000 claims description 89
- 238000003556 assay Methods 0.000 claims description 85
- 239000000203 mixture Substances 0.000 claims description 64
- 102000004190 Enzymes Human genes 0.000 claims description 49
- 108090000790 Enzymes Proteins 0.000 claims description 47
- 239000007791 liquid phase Substances 0.000 claims description 46
- 239000007787 solid Substances 0.000 claims description 46
- 239000007788 liquid Substances 0.000 claims description 44
- 210000004369 blood Anatomy 0.000 claims description 41
- 239000008280 blood Substances 0.000 claims description 41
- 238000002156 mixing Methods 0.000 claims description 29
- 102000007592 Apolipoproteins Human genes 0.000 claims description 27
- 108010071619 Apolipoproteins Proteins 0.000 claims description 27
- 230000002159 abnormal effect Effects 0.000 claims description 21
- 238000011534 incubation Methods 0.000 claims description 21
- 239000011159 matrix material Substances 0.000 claims description 19
- 238000004166 bioassay Methods 0.000 claims description 16
- 230000009871 nonspecific binding Effects 0.000 claims description 12
- 101710095342 Apolipoprotein B Proteins 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 4
- 101000889953 Homo sapiens Apolipoprotein B-100 Proteins 0.000 claims description 3
- 239000012071 phase Substances 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 102000052249 human APOB Human genes 0.000 claims 2
- 239000000376 reactant Substances 0.000 claims 1
- 238000002965 ELISA Methods 0.000 abstract description 23
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 93
- 102000015779 HDL Lipoproteins Human genes 0.000 description 81
- 108010010234 HDL Lipoproteins Proteins 0.000 description 81
- 239000000523 sample Substances 0.000 description 74
- 108010007622 LDL Lipoproteins Proteins 0.000 description 61
- 102000007330 LDL Lipoproteins Human genes 0.000 description 61
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 50
- 239000002953 phosphate buffered saline Substances 0.000 description 50
- 229940088598 enzyme Drugs 0.000 description 43
- 235000012000 cholesterol Nutrition 0.000 description 40
- 208000029078 coronary artery disease Diseases 0.000 description 40
- 239000000427 antigen Substances 0.000 description 38
- 230000027455 binding Effects 0.000 description 38
- 108091007433 antigens Proteins 0.000 description 36
- 102000036639 antigens Human genes 0.000 description 36
- 102000004169 proteins and genes Human genes 0.000 description 36
- 108090000623 proteins and genes Proteins 0.000 description 36
- 235000018102 proteins Nutrition 0.000 description 35
- 239000002245 particle Substances 0.000 description 30
- 102000004895 Lipoproteins Human genes 0.000 description 29
- 108090001030 Lipoproteins Proteins 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 29
- 206010003445 Ascites Diseases 0.000 description 28
- 210000002966 serum Anatomy 0.000 description 28
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 23
- 239000003153 chemical reaction reagent Substances 0.000 description 23
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 21
- 229940098773 bovine serum albumin Drugs 0.000 description 21
- 230000000890 antigenic effect Effects 0.000 description 20
- 239000012530 fluid Substances 0.000 description 18
- 150000002632 lipids Chemical class 0.000 description 18
- 238000010790 dilution Methods 0.000 description 17
- 239000012895 dilution Substances 0.000 description 17
- 238000003127 radioimmunoassay Methods 0.000 description 17
- 108010032595 Antibody Binding Sites Proteins 0.000 description 16
- 108010027006 Apolipoproteins B Proteins 0.000 description 16
- 230000036046 immunoreaction Effects 0.000 description 16
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical compound NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 15
- 102000018616 Apolipoproteins B Human genes 0.000 description 15
- 108010004103 Chylomicrons Proteins 0.000 description 15
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 15
- 239000000463 material Substances 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 230000008901 benefit Effects 0.000 description 12
- 239000000872 buffer Substances 0.000 description 12
- 201000001320 Atherosclerosis Diseases 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 10
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 9
- 230000002860 competitive effect Effects 0.000 description 9
- 239000000758 substrate Substances 0.000 description 9
- 229920001213 Polysorbate 20 Polymers 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000012153 distilled water Substances 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 150000003626 triacylglycerols Chemical class 0.000 description 8
- 238000012286 ELISA Assay Methods 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 description 7
- 239000004793 Polystyrene Substances 0.000 description 7
- 201000000050 myeloid neoplasm Diseases 0.000 description 7
- 229920002223 polystyrene Polymers 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 101800001976 Apolipoprotein B-48 Proteins 0.000 description 6
- 102400000352 Apolipoprotein B-48 Human genes 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 238000001155 isoelectric focusing Methods 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 6
- 230000001376 precipitating effect Effects 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 230000032258 transport Effects 0.000 description 6
- 229920000936 Agarose Polymers 0.000 description 5
- 238000008214 LDL Cholesterol Methods 0.000 description 5
- 239000003708 ampul Substances 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- -1 cholesterol Chemical class 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000000951 immunodiffusion Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000003118 sandwich ELISA Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102000009081 Apolipoprotein A-II Human genes 0.000 description 4
- 108010087614 Apolipoprotein A-II Proteins 0.000 description 4
- 102000006410 Apoproteins Human genes 0.000 description 4
- 108010083590 Apoproteins Proteins 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 102000000853 LDL receptors Human genes 0.000 description 4
- 108010001831 LDL receptors Proteins 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- 108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 description 4
- 102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000007982 barbital buffer Substances 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 230000001590 oxidative effect Effects 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 239000004800 polyvinyl chloride Substances 0.000 description 4
- 229920000915 polyvinyl chloride Polymers 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000004366 Glucose oxidase Substances 0.000 description 3
- 108010015776 Glucose oxidase Proteins 0.000 description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000473945 Theria <moth genus> Species 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000003599 detergent Substances 0.000 description 3
- 239000013024 dilution buffer Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 239000012847 fine chemical Substances 0.000 description 3
- 239000011888 foil Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 229940116332 glucose oxidase Drugs 0.000 description 3
- 235000019420 glucose oxidase Nutrition 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000004576 lipid-binding Effects 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 235000004252 protein component Nutrition 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000004988 splenocyte Anatomy 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- 238000003231 Lowry assay Methods 0.000 description 2
- 238000009013 Lowry's assay Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000005717 Myeloma Proteins Human genes 0.000 description 2
- 108010045503 Myeloma Proteins Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical group [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 108010059336 apolipoprotein B-26 Proteins 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 2
- 230000012953 feeding on blood of other organism Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000016784 immunoglobulin production Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000004816 latex Substances 0.000 description 2
- 229920000126 latex Polymers 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 2
- 230000008604 lipoprotein metabolism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000002731 protein assay Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000012857 radioactive material Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- AVQQQNCBBIEMEU-UHFFFAOYSA-N 1,1,3,3-tetramethylurea Chemical compound CN(C)C(=O)N(C)C AVQQQNCBBIEMEU-UHFFFAOYSA-N 0.000 description 1
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- ZTOJFFHGPLIVKC-UHFFFAOYSA-N 3-ethyl-2-[(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C1=NN=C1SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-UHFFFAOYSA-N 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- 101710112102 Apolipoprotein A-I-1 Proteins 0.000 description 1
- 102000018619 Apolipoproteins A Human genes 0.000 description 1
- 108010027004 Apolipoproteins A Proteins 0.000 description 1
- 102000013918 Apolipoproteins E Human genes 0.000 description 1
- 108010025628 Apolipoproteins E Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100328078 Bos taurus CL46 gene Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010023302 HDL Cholesterol Proteins 0.000 description 1
- 238000008470 HDL Cholesterol Assay Methods 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 108010046315 IDL Lipoproteins Proteins 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 241001536374 Indicator indicator Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 101150003479 Parg gene Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 230000010799 Receptor Interactions Effects 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 102000054727 Serum Amyloid A Human genes 0.000 description 1
- 101710190759 Serum amyloid A protein Proteins 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010065441 Venous haemorrhage Diseases 0.000 description 1
- 238000000333 X-ray scattering Methods 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000010420 art technique Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 235000015123 black coffee Nutrition 0.000 description 1
- 235000020279 black tea Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- KRVSOGSZCMJSLX-UHFFFAOYSA-L chromic acid Substances O[Cr](O)(=O)=O KRVSOGSZCMJSLX-UHFFFAOYSA-L 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000011365 complex material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000002298 density-gradient ultracentrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- SOCTUWSJJQCPFX-UHFFFAOYSA-N dichromate(2-) Chemical compound [O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O SOCTUWSJJQCPFX-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000003073 embolic effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 230000004545 gene duplication Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 102000035122 glycosylated proteins Human genes 0.000 description 1
- 108091005608 glycosylated proteins Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000012133 immunoprecipitate Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 108010059404 lipoprotein A-II Proteins 0.000 description 1
- 238000002761 liquid phase assay Methods 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036963 noncompetitive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000001448 refractive index detection Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001732 thrombotic effect Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/81—Packaged device or kit
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/948—Microorganisms using viruses or cell lines
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
- Y10S530/809—Fused cells, e.g. hybridoma
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
- Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
- Fats And Perfumes (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Arrangements For Transmission Of Measured Signals (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (13)
1. Förfarande för bestämning av ett markerande ämne för abnorm lipidmetabolism, vilket förfarande innefattar steg för bestämning av mängden av humant apolipoprotein B-100 och apolipoprotein A-I i blodprovets volymenhet och bestämning av förhällandet mellan apolipoprotein B-100 och apolipoprotein A-I i provet, k&nnetecknat av att (a) mängden av närvarande apolipoprotein B-100 bestäms frän det första alikvotet av det flytande blodprovet innehällande apolipoprotein B-100 hos en person sä, att: (i) det första nämnda flytande provalikvotet blandas med en fast bärare bestäende huvudsakligen av en fast matris inne-hällande de första monoklonala paratopiska molekylerna bund-na tili en fast fas, vilka molekyler immunoreagerar med apo-lipoproteinet B-100 och vilka avsöndras av den ena av hybri-domerna med ATCC-deponeringsnumret HB 8742 eller HB 8746, för bildning av den första blandningen av fast-vätskefas, varvid nämnda bärares yta innehäller skyddade, ospecifika bindningsställen; (ii) den första nämnda blandningen av fast-vätskefas inkube-ras under biologiska bestämningsbetingelser för en förutbe-stämd tidsperiod, som ur de första nämnda paratopiska mole-kylernas synpunkt räcker tili att immunoreagera med apolipo-proteinet B-100 närvarande i provalikvotet och att bilda en tili en fast fas bunden immunoreaktant innehällande väsent-ligen allt apolipoprotein B-100 närvarande i nämnda provali-kvot; (iii) apolipoproteinet B-100 i nämnda första flytande provalikvotet blandas med andra monoklonala paratopiska molekyler av vätskefas, vilka molekyler immunoreagerar med apolipoproteinet B-100 och vilka avsöndras av den ena av hybrido-merna med ATCC-deponeringsnumret HB 8742 och HB 8746, men vilka inte används i steget (a) (i), och vilka är funk-tionellt bundna tili en enzymindikator, för bildning av den andra blandningen; (iv) den andra nämnda blandningen inkuberas under biologiska bestämningsbetingelser för en förutbestämd tidsperiod, som θο 8921 4 ur de andra nämnda tili indikatorn bundna paratopiska mole-kylernas synpunkt räcker tili att bilda en immunoreaktant, som innehäller väsentligen allt apolipoprotein B-100 närva-rande i provalikvotet; (v) de fasta och de vätskeformiga f asema separeras, vilka resulterar frän föregäende stegen (a) (i-iv) ; och (vi) i den separerade fasta fasen närvarande mängden av im-munoreaktanten innehällande det tili indikatorn bundna apo-lipoproteinet B-100, och säledes mängden av apolipoproteinet B-100 i provets volymenhet bestäms; (b) det andra alikvotet bestäms av nämnda flytande blodprov innehällande apolipoprotein A-I, och som inte har behandlats att avlägsna skyddning, för närvarande av apolipoprotein A-I sä, att: (i) det andra nämnda flytande provalikvotet blandas med en fast bärare bestäende huvudsakligen av en fast matris inne-hällande de tredje monoklonala paratopiska molekylerna bundna tili en fast fas, vilka molekyler immunoreagerar med apolipoproteinet A-I och vilka avsöndras av den ena av hybrido-merna med ATCC-deponeringsnumret HB 9200 eller HB 9201, för bildning av den tredje blandningen av fast-vätskefas, varvid nämnda fasta bärares yta innehäller skyddade, ospecifika bindningsställen; (ii) den tredje nämnda blandningen av fast-vätskefas inkube-ras under biologiska bestämningsbetingelser för en förutbe-stämd tidsperiod, som ur de tredje nämnda paratopiska mole-kylernas synpunkt räcker tili att immunoreagera med apolipoproteinet A-I närvarande i provalikvotet och att bilda en tili en fast fas bunden immunoreaktant innehällande väsent-ligen allt apolipoprotein A-I närvarande i provalikvotet; (iii) apolipoproteinet A-I i det nämnda andra flytande provalikvotet blandas med de fjärde monoklonala paratopiska molekylerna av vätskefas, vilka molekyler immunoreagerar med apolipoproteinet A-I, och vilka avsöndras av den ena av hyb-ridomerna med ATCC-deponeringsnumret HB 9200 eller HB 9201, men vilka inte används i steget (b) (i) , och vilka är funk- 8i 8921 4 tionellt bundna till en enzymindikator, för bildning av den fjärde blandningen; (iv) den fjärde nämnda blandningen inkuberas under biologis-ka bestämningsbetingelser för en förutbestämd tidsperiod, som ur de fjärde nämnda tili indikatorn bundna paratopiska molekylernas synpunkt räcker tili att bilda en immunoreak-tant med väsentligen allt apolipoprotein A-I närvarande i provalikvotet; (v) de fasta och de vätskeformiga faserna, vilka resulterar frän föregäende stegen (b) (i-iv) separeras; och (vi) i den separerade fasta fasen närvarande mängden av im-munoreaktanten innehällande det tili indikatorn bundna apo-lipoproteinet A-I, och säledes mängden av apolipoproteinet A-I i provets volymenhet bestäms.
2. Förfarande enligt patentkrav 1, kännetecknat av att nämnda blandningssteg (a) (i) och (a) (iii) utförs väsentligen samtidigt, och nämnda inkuberingssteg (a) {ii) och (a) (iv) utförs tillsammans.
3. Förfarande enligt patentkrav 1, kännetecknat av att de fasta och vätskeformiga faserna närvarande efter steget (a) (ii), separeras före steget (a) (iii), och att apolipoproteinet B-100, som blandas i steget (a) (iii), i det första nämnda flytande alikvotet är närvarande i en tili en fast fas bunden immunoreaktant, som bildas i steget (a) (ii).
4. Förfarande enligt patentkrav 1, kännetecknat av att de fasta och vätskeformiga faserna närvarande efter steget (b) (ii), separeras före steget (b) (iii), och att apolipoproteinet A-I, som blandas i steget (b) (iii), i det andra nämnda flytande alikvotet är närvarande i en tili en fast fas bunden immunoreaktant, som bildas i steget (b) (ii).
5. Förfarande enligt patentkrav 1, kännetecknat av att nämnda blandningssteg (b) (i) och (b) (iii) utförs väsentligen samtidigt, och nämnda inkuberingssteg (b) (ii) och (b) (iv) utförs tillsammans. 82 8921 4
6. Förfarande för bestämning av ett markerande ämne för abnorm lipidmetabolism, vilJcet förfarande innefattar steg för bestämning av mängden av humant apolipoprotein B-100 och apolipoprotein A-l i blodprovets volymenhet och bestämning av förhällandet mellan apolipoprotein B-100 och apolipoprotein A-I i provet, kännetecknat av att (a) mängden av närvarande apolipoprotein B-100 bestäms frän det första alikvotet av det flytande blodprovet innehällande det första apolipoproteinet B-100 hos en person sä, att: (i) det första blandningen av fast-vätskefas bildas genom väsentligen samtidig blandning av nämnda första flytande provalikvot med en fast bärare bestäende huvudsakligen av en fast matris innehällande första monoklonala paratopiska mo-lekylerna bundna tili en fast fas, vilka molekyler immuno-reagerar med apolipoproteinet B-100 och vilka avsöndras av den ena av hybridomerna med ATCC-deponeringsnumret HB 8742 eller HB 8746, och andra monoklonala paratopiska molekyler, vilka är funktionellt bundna tili en enzymindikator, och vilka avsöndras av den ena av hybridomerna med ATCC-deponeringsnumret HB 8742 och HB 8746, men är inte de första paratopiska molekylerna, och vilka är bundna tili en fast matris, varvid nämnda bärares yta innehäller skyddade, ospe-cifika bindningsställen; (ii) den första nämnda blandningen av fast-vätskefas inkube-ras under biologiska bestämningsbetingelser för en förutbe-stämd tidsperiod, som ur de första nämnda paratopiska mole-kylernas synpunkt räcker tili, och ur de nämnda tili indika-torn bundna andra paratopiska molekylernas synpunkt räcker tili att immunoreagera med väsentligen allt apolipoprotein B-100 närvarande i provalikvotet för bilding av en tili en fast fas bunden sandwich-immunoreaktant och en vätskeformig fas ; (iii) de fasta och de vätskef ormiga f asema separeras; och (vi) i den separerade fasta fasen närvarande mängden av sandwich-immunoreaktanten innehällande det tili indikatorn bundna apolipoproteinet B-100, och säledes mängden av apolipoproteinet B-100 i provets volymenhet bestäms; 83 8 9 2 1 4 (b) det andra alikvotet bestäms av nämnda flytande blodprov innehällande apolipoprotein A-I, och som inte har behandlats att avlägsna skyddning, för närvarande av apolipoprotein A-I sd, att: (i) den andra blandningen av fast-vätskefas bildas genom väsentigen samtidig blandning av nämnda andra flytande pro-valikvotet med en fast bärare bestdende huvudsakligen av en fast matris innehällande tredje monoklonala paratopiska mo-lekyler bundna tili en fast fas, vilka molekyler immuno-reagerar med apolipoproteinet A-I och vilka avsöndras av den ena av hybridomerna med ATCC-deponeringsnumret HB 9200 eller HB 9201, och fjärde monoklonala paratopiska molekyler funk-tionellt bundna tili en enzymindikator, och vilka avsöndras av den ena av hybridomerna med ATCC-deponeringsnumret HB 9200 eller HB 9201, och inte är de tili en fast fas bundna tredje paratopiska molekylerna, varvid nämnda bärares yta innehäller skyddade ospecifika bindningställen; (ii) den andra nämnda blandningen av fast-vätskefas inkube-ras under biologiska bestämningsbetingelser för en förutbe-stämd tidsperiod, som ur de tredje nämnda paratopiska mole-kylernas och ur de fjärde nämnda tili indikatorn bundna paratopiska molekylernas synpunkt räcker tili att immunoreage-ra med väsentligen allt apolipoprotein A-I närvarande i pro-valikvotet för bildning av en tili en fast fas bunden sandwich- reaktant och vätskefas; (iii) de fasta och de vätskeformiga f asema separeras; och (iv) i den separerade fasta fasen närvarande mängden av sandwich-immunoreaktanten innehällande det tili indikatorn bundna apolipoproteinet A-I, och säledes mängden av apolipoproteinet A-I i provets volymenhet bestäms.
7. Förfarande enligt patentkrav 6, k&nnetecknat av att de nämnda första paratopiska molekylerna avsöndras av hybrido-man med ATCC-numret HB 8746. 84 8921 4
8. Förfarande enligt patentkrav 6, kännetecknat av att de nämnda tredje paratopiska molekylerna avsöndras av hybrido-man med ATCC-numret HB 9200.
9. Förfarande enligt patentkrav 6, kännetecknat av att nämn-da inkubering under de biologiska bestämningsbetingelserna i stegen (a) (ii) och (b) (ii) varar cirka 30 minuter - cirka 60 minuter vid rädande rumstemperatur.
10. Förfarande enligt patentkrav 9, kännetecknat av att nämnda inkubering varar cirka 30 minuter och den utförs med omröring.
11. Diagnostiskt system som lämpar sig att användas vid be-stämning av förhällandet mellan apolipoproteinet B-100 och apolipoproteinet A-I i ett flytande blodprov, kännetecknat av att systemet innefattar: a) den första behällaren innehällande paratopiska molekyler, som immunoreagerar med apolipoproteinet B-100 och som avsöndras av den ena av hybridomerna med ATCC-numret HB 8742 el-ler HB 8746; b) den andra behällaren innehällande paratopiska molekyler, som immunoreagerar med apolipoproteinet B-100 och som avsöndras av den ena av hybridomerna med ATCC-numret HB 8742 el-ler HB 8746, men inte ingär i den första behällaren och är funktionellt bundna tili en enzymindikator; c) den tredje behällaren innehällande paratopiska molekyler, som immunoreagerar med apolipoproteinet A-I och som avsöndras av den ena av hybridomerna med ATCC-numret HB 9200 el-ler HB 9201; och d) den fjärde behällaren innehällande paratopiska molekyler, som immunoreagerar med apolipoproteinet A-I och som avsöndras av den ena av hybridomerna med ATCC-numret HB 9200 el-ler HB 9201, men inte ingär i den tredje behällaren och är funktionellt bundna tili en enzymindikator; varvid var och en av de paratopiska molekylerna är närvaran-de i en mängd, som räcker tili att utföra en bestämning av nämnda förhällande mellan apolipoproteinerna. 85 8921 4
12. Diagnostiskt system enligt patentkrav 11, kannetecknat av att de motsvarande monoklonala paratopiska molekyler, som immunoreagerar med apolipoproteinet B-100 och apolipopro-teinet A-I, vilka molekyler inte är bundna till nämnda motsvarande indikator, är var och en skilt bundna till en matris av fast fas för bildning av skilda fasta bärare, varvid nämnda bärares ytor innehäller skyddade ospecifika bindningställen.
13. Diagnostiskt system enligt patentkrav 12, kannetecknat av att de monoklonala paratopiska molekyler, som avsöndras av hybridomerna med ATCC-deponeringsnumret HB8746 och 9200, är bundna till nämnda skilda fasta matriser.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91314086 | 1986-09-29 | ||
| US06/913,140 US4828986A (en) | 1986-09-29 | 1986-09-29 | Assay method and diagnostic system for determining the ratio of APO B-100 to APO A-I in a blood sample |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| FI874253A0 FI874253A0 (fi) | 1987-09-28 |
| FI874253L FI874253L (fi) | 1988-03-30 |
| FI89214B true FI89214B (fi) | 1993-05-14 |
| FI89214C FI89214C (sv) | 1993-08-25 |
Family
ID=25432962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI874253A FI89214C (sv) | 1986-09-29 | 1987-09-28 | Analysförfarande och diagnostiskt system för ett markerande ämne för a bnorm lipidmetabolism |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US4828986A (sv) |
| EP (1) | EP0262854B1 (sv) |
| JP (1) | JP2656774B2 (sv) |
| AT (1) | ATE85435T1 (sv) |
| AU (1) | AU611096B2 (sv) |
| CA (1) | CA1285869C (sv) |
| DE (1) | DE3783991T2 (sv) |
| DK (1) | DK173724B1 (sv) |
| ES (1) | ES2053555T3 (sv) |
| FI (1) | FI89214C (sv) |
| GR (1) | GR3008027T3 (sv) |
| IE (1) | IE60119B1 (sv) |
| IL (1) | IL83938A (sv) |
| NO (1) | NO173902C (sv) |
| NZ (1) | NZ221941A (sv) |
| PT (1) | PT85827B (sv) |
| ZA (1) | ZA876970B (sv) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE120233T1 (de) * | 1986-08-06 | 1995-04-15 | Scripps Clinic Res | Monoklonale antikörper, b-spezifisch für apolipoprotein, die von zwei hybridomen erzeugt werden. |
| DE3734015A1 (de) * | 1987-10-08 | 1989-04-20 | Behringwerke Ag | Diagnostisches mittel und verfahren zur bestimmung von apolipoprotein b |
| AU621575B2 (en) * | 1987-11-02 | 1992-03-19 | Scripps Clinic And Research Foundation | Diagnostic methods and systems for quantifying apo ai |
| US5759774A (en) * | 1988-05-18 | 1998-06-02 | Cobe Laboratories, Inc. | Method of detecting circulating antibody types using dried or lyophilized cells |
| US5183738A (en) * | 1988-09-29 | 1993-02-02 | Japan Immuno Research Laboratories Co., Ltd. | Kit for the detection of denatured lipoproteins |
| US5179008A (en) * | 1989-02-09 | 1993-01-12 | Wisconsin Alumni Research Foundation | Hybridoma and monoclonal antibody to FHAP |
| US5473039A (en) * | 1989-08-18 | 1995-12-05 | The Scripps Research Institute | Polypeptide analogs of apolipoprotein E, diagnostic systems and methods using the analogs |
| US5168045A (en) * | 1989-08-18 | 1992-12-01 | The Scripps Research Institute | Diagnostic systems and methods using polypeptide analogs of apolipoprotein e |
| AU662885B2 (en) * | 1990-06-07 | 1995-09-21 | Scripps Research Institute, The | APO AI polypeptides, antibodies, and immunoassays |
| WO1992009893A1 (en) * | 1990-11-29 | 1992-06-11 | Carbaugh John E | DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS FOR LIPOPROTEIN(a) |
| US5844097A (en) * | 1990-11-30 | 1998-12-01 | Monoclonetics International, Inc. | Methods for the diagnosis of peripheral nerve damage |
| DK0559795T3 (da) * | 1990-11-30 | 1996-01-29 | Monoclonetics Int | Fremgangsmåder til diagnosticering af kroniske smerter i lænderegionen og halshvrivelsøjlen |
| US5408038A (en) * | 1991-10-09 | 1995-04-18 | The Scripps Research Institute | Nonnatural apolipoprotein B-100 peptides and apolipoprotein B-100-apolipoprotein A-I fusion peptides |
| WO1994007146A1 (en) * | 1992-09-24 | 1994-03-31 | Perseptive Biosystems, Inc. | Quantitative measurement of ldl |
| US6107045A (en) * | 1994-06-30 | 2000-08-22 | Oklahoma Medical Research Foundation | Antibodies to lipoproteins and apolipoproteins and methods of use thereof |
| US5994061A (en) * | 1995-09-29 | 1999-11-30 | Queen's University At Kingston | DNA constructs and methods for screening for increased expression of human apo AI gene |
| US5741647A (en) * | 1996-02-16 | 1998-04-21 | Tam; Joseph Wing On | Flow through nucleic acid hybridisation uses thereof and a device thereof |
| US6248539B1 (en) | 1997-09-05 | 2001-06-19 | The Scripps Research Institute | Porous semiconductor-based optical interferometric sensor |
| EP0911344B1 (en) | 1997-10-15 | 2004-03-03 | Fujirebio Inc. | Anti-Apo-B-48 monoclonal antibody, hybridoma, and methods of use |
| AT5044U1 (de) * | 2001-05-10 | 2002-02-25 | Medsystems Diagnostics Gmbh | Quantitativer einschritt immuntest in lyophilisierter form |
| DE60237455D1 (de) * | 2001-07-12 | 2010-10-07 | Kyowa Medex Co Ltd | Verfahren zur quantifizierung von denaturiertem lipoprotein |
| US7781171B2 (en) | 2003-10-15 | 2010-08-24 | Daiichi Pure Chemicals Co., Ltd. | Mehod of pretreating sample and immunological assay method using the same |
| JP4669929B2 (ja) * | 2003-10-15 | 2011-04-13 | 積水メディカル株式会社 | 試料の前処理方法及びこれを利用する免疫学的測定方法 |
| US7521248B2 (en) * | 2007-04-20 | 2009-04-21 | Atherotech, Inc. | Apo B measurement system and method |
| EP3435089A1 (en) | 2011-11-11 | 2019-01-30 | Axis-Shield AS | Determination of non-hdl cholesterol in blood |
| CN118047854B (zh) * | 2024-02-26 | 2024-08-02 | 武汉鹰达生物科技有限公司 | 一种人载脂蛋白a-i的分离纯化方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2061282B (en) * | 1979-10-22 | 1983-03-30 | Symphar Sa | Method for the clinical separation of a-and lipoproteins and kit for carrying out this method |
| US4376110A (en) * | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| JPS60193926A (ja) * | 1984-03-15 | 1985-10-02 | Tokyo Daigaku | 単クローン性抗ヒトアポリポ蛋白質ｂ１００抗体 |
| JPS60253871A (ja) * | 1984-05-30 | 1985-12-14 | Nippon Koutai Kenkyusho:Kk | 抗アポａ−１抗体 |
| EP0209543A4 (en) * | 1984-12-31 | 1989-07-11 | Internat Genetic Engineering I | FRAGMENTS OF HUMAN APOLIPOPROTEINS PEPTIDES, TYPE-SPECIFIC ANTIBODIES AND METHODS OF USE. |
| US4677057A (en) * | 1985-03-11 | 1987-06-30 | Scripps Clinic And Research Foundation | Diagnostic assay for the presence of apolipoproteins associated with plasma high density lipoproteins |
-
1986
- 1986-09-29 US US06/913,140 patent/US4828986A/en not_active Expired - Lifetime
-
1987
- 1987-09-16 ZA ZA876970A patent/ZA876970B/xx unknown
- 1987-09-17 IL IL83938A patent/IL83938A/xx not_active IP Right Cessation
- 1987-09-22 EP EP87308392A patent/EP0262854B1/en not_active Expired - Lifetime
- 1987-09-22 DE DE8787308392T patent/DE3783991T2/de not_active Expired - Lifetime
- 1987-09-22 AT AT87308392T patent/ATE85435T1/de not_active IP Right Cessation
- 1987-09-22 ES ES87308392T patent/ES2053555T3/es not_active Expired - Lifetime
- 1987-09-25 NZ NZ221941A patent/NZ221941A/xx unknown
- 1987-09-28 CA CA000547941A patent/CA1285869C/en not_active Expired - Lifetime
- 1987-09-28 FI FI874253A patent/FI89214C/sv not_active IP Right Cessation
- 1987-09-28 AU AU79028/87A patent/AU611096B2/en not_active Expired
- 1987-09-28 IE IE260587A patent/IE60119B1/en not_active IP Right Cessation
- 1987-09-28 DK DK198705092A patent/DK173724B1/da not_active IP Right Cessation
- 1987-09-28 NO NO874056A patent/NO173902C/no unknown
- 1987-09-29 JP JP62245737A patent/JP2656774B2/ja not_active Expired - Lifetime
- 1987-09-29 PT PT85827A patent/PT85827B/pt unknown
-
1993
- 1993-04-30 GR GR920403215T patent/GR3008027T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2053555T3 (es) | 1994-08-01 |
| ATE85435T1 (de) | 1993-02-15 |
| GR3008027T3 (sv) | 1993-09-30 |
| DE3783991D1 (de) | 1993-03-18 |
| US4828986A (en) | 1989-05-09 |
| FI874253L (fi) | 1988-03-30 |
| NO874056D0 (no) | 1987-09-28 |
| FI89214C (sv) | 1993-08-25 |
| NZ221941A (en) | 1989-05-29 |
| NO874056L (no) | 1988-03-30 |
| DK509287D0 (da) | 1987-09-28 |
| IE872605L (en) | 1988-03-29 |
| EP0262854A2 (en) | 1988-04-06 |
| PT85827B (pt) | 1990-08-31 |
| NO173902C (no) | 1994-02-16 |
| AU7902887A (en) | 1988-03-31 |
| PT85827A (en) | 1987-10-01 |
| EP0262854B1 (en) | 1993-02-03 |
| NO173902B (no) | 1993-11-08 |
| IE60119B1 (en) | 1994-06-01 |
| DE3783991T2 (de) | 1993-06-09 |
| JP2656774B2 (ja) | 1997-09-24 |
| DK173724B1 (da) | 2001-07-30 |
| IL83938A0 (en) | 1988-02-29 |
| CA1285869C (en) | 1991-07-09 |
| ZA876970B (en) | 1988-03-21 |
| DK509287A (da) | 1988-03-30 |
| IL83938A (en) | 1991-12-15 |
| JPS63277968A (ja) | 1988-11-15 |
| EP0262854A3 (en) | 1989-12-06 |
| AU611096B2 (en) | 1991-06-06 |
| FI874253A0 (fi) | 1987-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI89214B (fi) | Analysfoerfarande och diagnostiskt system foer ett markerande aemne foer abnorm lipidmetabolism | |
| FI92715C (sv) | Monoklonal paratop molekyl och hybridom som utsöndrar den för bestämning av apolipoprotein A-I | |
| US4677057A (en) | Diagnostic assay for the presence of apolipoproteins associated with plasma high density lipoproteins | |
| MXPA01010995A (es) | Un anticuerpo monoclonal contra la leucina aminopeptidasa estimulada por estrogenos. | |
| EP0741144B1 (en) | Antiannexin-v monoclonal antibody, process for producing the same, and use therof | |
| US5330910A (en) | Apolipoprotein B-specific monoclonal antibodies produced by two novel hybridomas | |
| JPWO1996015152A1 (ja) | 抗アネキシンｖモノクローナル抗体並びにその製法及びその利用 | |
| CA1247023A (en) | Diagnostic assay for the presence of apolipoproteins associated with plasma high density lipoproteins |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB | Publication of examined application | ||
| FD | Application lapsed | ||
| FG | Patent granted |
Owner name: SCRIPPS CLINIC AND RESEARCH FOUNDATION |
|
| MA | Patent expired |